Focal adhesion kinase 1 (PTK2) (FAK)

Focal adhesion kinase 1 (FAK), also known as Protein-tyrosine kinase 2 (PTK2), is a cytoplasmic non-receptor tyrosine kinase that serves as a key mediator of integrin-mediated signal transduction [UniProt: Q05397]. The protein is characterized by an N-terminal FERM domain, a central kinase domain, and a C-terminal Focal Adhesion Targeting (FAT) domain, the latter of which is essential for its localization to focal adhesions through interactions with proteins like paxillin [PMID: 11526502]. FAK regulates critical cellular processes such as adhesion, migration, proliferation, and survival by acting as both a signaling enzyme and a scaffold for other proteins [UniProt: Q05397, PMID: 22439937]. In many human cancers, FAK is overexpressed or hyperactivated, contributing to tumor invasion, metastasis, and the maintenance of a pro-tumorigenic microenvironment [PMID: 22439937]. Consequently, FAK has become a significant therapeutic target, with several small-molecule inhibitors currently in clinical trials aimed at blocking its kinase activity or disrupting its scaffolding functions [DrugBank: DB12634]. Beyond oncology, FAK is also being investigated for its role in fibrotic diseases and cardiovascular health [PMID: 22439937]. The FAT domain specifically is a four-helix bundle that mediates protein-protein interactions, making it a distinct site for developing inhibitors that disrupt FAK's recruitment to focal sites [PMID: 11526502].

Other names

Protein-tyrosine kinase 2PTK2pp125FAKFADK 1Focal adhesion kinase-related non-kinase (FRNK)FAT domain

Small molecule inhibition of the kinase domain (ATP-competitive) to prevent autophosphorylation at Tyr397, or disruption of the focal adhesion targeting (FAT) domain interactions to prevent localization and scaffolding functions [PMID: 22439937, PMID: 11526502].